eligibility_summary
Inclusion: Adults (≥18) with treatment‑naive, path‑confirmed CD20+ follicular lymphoma grade 1–3A (2016 WHO), indications for therapy, measurable disease on CT/PET‑CT, suitable for GR/GB/G‑CHOP, and consented. Exclusion: transformed or grade 3B FL, active HBV/HCV or HIV, CNS/meningeal involvement, contraindications to planned drugs, or judged unsuitable by investigators.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Non-interventional real-world study in untreated CD20+ follicular lymphoma assessing obinutuzumab-based regimens: GR (obinutuzumab + lenalidomide), GB (obinutuzumab + bendamustine), and GCHOP (obinutuzumab + cyclophosphamide, doxorubicin, vincristine, prednisone), with obinutuzumab maintenance. Mechanisms/types: Obinutuzumab—type II anti-CD20 monoclonal antibody immunotherapy, depletes malignant B cells via ADCC/ADCP and direct cell death. Lenalidomide—oral IMiD, binds cereblon (CRL4CRBN), degrades IKZF1/3, boosts T/NK activity and ADCC, anti-angiogenic. Bendamustine/cyclophosphamide—alkylating DNA crosslinkers. Doxorubicin—anthracycline/topoisomerase II inhibitor. Vincristine—microtubule inhibitor. Prednisone—glucocorticoid, lympholytic. Targets/pathways: CD20+ B cells, cereblon–IKZF signaling, immune effector (NK/T) ADCC, DNA damage/apoptosis, topoisomerase II, microtubules, glucocorticoid receptor.